HomeBiotech

Biotech

FDA Roundup: September 27, 2024

FDA Roundup: September 27, 2024

September 28, 2024

FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

September 27, 2024

Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer

Anbogen Announces Drug Supply Collaboration with BeiGene to Evaluate Combination Therapy in Colorectal Cancer

September 27, 2024

Breakthrough Therapy Designation (BTD) for BioCity’s SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria

Breakthrough Therapy Designation (BTD) for BioCity’s SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria

September 26, 2024

AVANT BIO Announces Investments in Nomic Bio, PathPresenter, and PL BioScience

AVANT BIO Announces Investments in Nomic Bio, PathPresenter, and PL BioScience

September 26, 2024

Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024

Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024

September 25, 2024

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

September 25, 2024

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

September 24, 2024

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting

September 24, 2024

Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024

Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024

September 23, 2024

« 1 … 11 12 13 14 15 … 75 »